{"DataElement":{"publicId":"2741552","version":"1","preferredName":"Radiolabeled Monoclonal Antibody Preparative Regimen Type","preferredDefinition":"A description of the radiolabeled monoclonal antibody that was used as a preparative regimen.","longName":"RMAB_PRP_REG_TYPE","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2741521","version":"1","preferredName":"Radiolabeled Monoclonal Antibody Preparative Regimen Type","preferredDefinition":"Any compound that has been joined with a radioactive substance._An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment._The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._Something distinguishable as an identifiable class based on common qualities.","longName":"RMAB_PRP_RG_TP","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2741519","version":"1","preferredName":"Radiolabeled Monoclonal Antibody Preparative Regimen","preferredDefinition":"Any compound that has been joined with a radioactive substance.:An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.:The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur.","longName":"C18138:C20401:C61155","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiolabeled","conceptCode":"C18138","definition":"Any compound that has been joined with a radioactive substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-459B-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"ONEDATA","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223243","version":"1","preferredName":"Type","preferredDefinition":"A subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F629F5E5-DE63-1DFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-45A9-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2741547","version":"1","preferredName":"Radiolabeled Monoclonal Antibody Type","preferredDefinition":"Any compound that has been joined with a radioactive substance._An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment._Type; a subdivision of a particular kind of thing.","longName":"RMAB_TYPE","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"21","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Tositumomab (Bexxar)","valueDescription":"Tositumomab","ValueMeaning":{"publicId":"2741550","version":"1","preferredName":"Tositumomab","longName":"2741550","preferredDefinition":"A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tositumomab","conceptCode":"C2543","definition":"A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-4641-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F8E0B78-BC2E-6CAC-E044-0003BA3F9857","beginDate":"2008-04-15","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-06-13","modifiedBy":"NYCHM","dateModified":"2008-06-13","deletedIndicator":"No"},{"value":"Radiolabeled MAb","valueDescription":"Radiolabeled Monoclonal Antibody","ValueMeaning":{"publicId":"2751256","version":"1","preferredName":"Radiolabeled Monoclonal Antibody","longName":"2751256","preferredDefinition":"Any compound that has been joined with a radioactive substance.: An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiolabeled","conceptCode":"C18138","definition":"Any compound that has been joined with a radioactive substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DBEFD1A-1424-6963-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4DBEFD1A-143D-6963-E044-0003BA3F9857","beginDate":"2008-05-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-21","modifiedBy":"ALEYR","dateModified":"2008-05-21","deletedIndicator":"No"},{"value":"Other rMAb","valueDescription":"Other Radiolabeled Monoclonal Antibody","ValueMeaning":{"publicId":"2741548","version":"1","preferredName":"Other Radiolabeled Monoclonal Antibody","longName":"2741548","preferredDefinition":"Not otherwise specified.: Any compound that has been joined with a radioactive substance.: An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Radiolabeled","conceptCode":"C18138","definition":"Any compound that has been joined with a radioactive substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-45F3-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AEC075A-460C-26F2-E044-0003BA3F9857","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"ALEYR","dateModified":"2008-04-15","deletedIndicator":"No"},{"value":"Ibritumomab (Zevalin)","valueDescription":"Ibritumomab Tiuxetan","ValueMeaning":{"publicId":"2741549","version":"1","preferredName":"Ibritumomab Tiuxetan","longName":"2741549","preferredDefinition":"ZEVALIN (Ibritumomab Tiuxetan) is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody Ibritumomab and the linker-chelator tiuxetan.  This linker-chelator provides a high affinity, conformationally restricted chelation site for Indium-111 or Yttrium-90.  The ZEVALIN therapeutic regimen is administered in two steps: Step 1 includes one infusion of Rituximab preceding In-111 ZEVALIN. Step 2 follows Step 1 by seven to nine days and consists of a second infusion of Rituximab followed by Y-90 ZEVALIN.  ZEVALIN is supplied as two separate and distinctly labeled kits that contain all of the non-radioactive ingredients necessary to produce a single dose of In-111 ZEVALIN and a single dose of Y-90 ZEVALIN, both essential components of the ZEVALIN therapeutic regimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibritumomab Tiuxetan","conceptCode":"C29981","definition":"An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-461A-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AEC075A-4633-26F2-E044-0003BA3F9857","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"ALEYR","dateModified":"2008-04-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2741546","version":"1","preferredName":"Radiolabeled Monoclonal Antibody Type","preferredDefinition":"Any compound that has been joined with a radioactive substance.:An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.:Type; a subdivision of a particular kind of thing.","longName":"C18138:C20401:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiolabeled","conceptCode":"C18138","definition":"Any compound that has been joined with a radioactive substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-45C9-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"ONEDATA","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-45DA-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2842912","version":"1","longName":"Therapy","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2842913","version":"1","longName":"Best Response","context":"NHLBI"},{"publicId":"2842917","version":"1","longName":"Supportive","context":"NHLBI"},{"publicId":"2865266","version":"1","longName":"Drug","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"Product:typeCode","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What type of radiolabeled mon","type":"Preferred Question Text","description":"What type of radiolabeled monoclonal antibody was used as a preparative regimen?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2741552","type":"BRIDG Mapping Path","description":"PerformedSubstanceAdministration > StudyAgent > Product.typeCode WHERE  Product.classCode = \"Mono Clonal Antibody\" AND PerformedSubstanceAdministration > DefinedSubstanceAdministration > DefinedCompositionRelationship > DefinedSubjectActivityGroup.nameCode = \"Perform preparative regimen\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-466F-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"KUMMEROA","dateModified":"2021-04-28","changeDescription":". 2021-4-28 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}